Abiomed Inc.

ABMD

$327.14

+8.6% (1 year change)

Market Cap

$14.7 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$242.73 - $387.40

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

65.31x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $14.7 Billion
Enterprise Value $14.1 Billion
Dividend Yield $0.00 (0.0%)
1 Year Return +8.6%
52-Week High $387.40
52-Week Low $242.73
Beta 0.94
Outstanding Shares 45.3 Million
Avg 30 Day Volume 177 Thousand

Valuation

P/E Ratio 65.31
PEG 82.87
Earnings per Share $4.94
Price to Sales Ratio 18.17
Price to Book Ratio 11.28
Revenue to Enterprise Value 16.69
EBIT to Enterprise Value 61.62
Total Debt to Enterprise Value 0.0
Debt to Equity 0.0

Profitability

Revenue $848 Million
Gross Profit $686 Million
EBIT $230 Million
Net Income $226 Million
Profit Margin 26.61%
Quarterly Earnings Growth (YoY) +78.8%
Return on Equity 16.96%
Return on Assets 15.09%
Return on Invested Capital 16.81%

Abiomed Inc.

Abiomed is a publicly-traded medical devices company that develops and manufactures the circulatory support device Impella, the world’s smallest heart pump. The company is headquartered in Danvers, Massachusetts and has three additional offices, two in Germany in the cities of Berlin and Aachen, and another in Tokyo, Japan. Michael R. Minogue is Chairman, CEO & President of the company, with Dr. Thorsten Siess as Chief Technology Officer, Dr. Chuck Simonton as Chief Medical Officer and Dr. David M. Weber as Chief Operating Officer. According to Bloomberg, the company "engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients". As of 2019, the company had secured five FDA approvals and 715 patents with 622 pending. For fiscal year 2019, Abiomed reported $769.4 million in revenue and reported diluted earnings per share was $5.61 for the year. Abiomed was founded in Danvers, Massachusetts by David M. Lederman in 1981 as Applied Biomedical Corporation. That year, the company commenced the development of an artificial heart. Funded by federal research grants, Lederman partnered with The Texas Heart Institute to develop the AbioCor, a grapefruit-sized electromagnetic device with an internal battery that completely replaces the heart without wires or tubes passing through the skin. In July 2001, AbioCor became the first artificial heart successfully implanted in a patient, where it pumped more than 20 million times. Fourteen of the AbioCor devices were implanted, during clinical trials from 2001 to 2004, with the longest-living recipient surviving 512 days. The AbioCor won FDA approval in 2006 for patients who are near death and do not qualify for a heart transplant.

News

Artificial Organ And Bionics Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Abiomed Inc., Asahi Kasei Kuraray Medical Co. Ltd., Thoratec Corporation, WorldHear

Artificial Organ And Bionics Market 2021 SWOT Analysis, Competitive Landscape and Significant Growth | Top Brands:Abiomed Inc., Asahi Kasei Kuraray Medical Co. Ltd., Thoratec Corporation, WorldHear

This report studies the Artificial Organ And Bionics Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief informat...

Jumbo News Jumbo News, 7 days ago
Ventricular Assist Device Market 2021 Precise Outlook- Abiomed Inc., BiVACOR Inc, Abbott Laboratories

Ventricular Assist Device Market 2021 Precise Outlook- Abiomed Inc., BiVACOR Inc, Abbott Laboratories

The Ventricular Assist Device market is a comprehensive market research report which provides market analysis with a historical & futuristic perspective for the following parameters; market size, r...

OpenPR OpenPR, 16 days ago
Here is What Hedge Funds Think About ABIOMED, Inc. (ABMD)

Here is What Hedge Funds Think About ABIOMED, Inc. (ABMD)

No summary available.

Insider Monkey Insider Monkey, 18 days ago